Evidence map›Paper›PMID 30696301›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2019

Inhibition of protein phosphatase-1 and -2A by ellagitannins: structure-inhibitory potency relationships and influences on cellular systems.

Zoltán Kónya, Bálint Bécsi, Andrea Kiss, Dániel Horváth, Mária Raics, Katalin E Kövér, Beáta Lontay, Ferenc Erdődi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zoltán Kónyaa Department of Medical Chemistry, Faculty of Medicine , University of Debrecen , Debrecen , Hungary.
Bálint Bécsia Department of Medical Chemistry, Faculty of Medicine , University of Debrecen , Debrecen , Hungary.
Andrea Kissa Department of Medical Chemistry, Faculty of Medicine , University of Debrecen , Debrecen , Hungary.
Dániel Horvátha Department of Medical Chemistry, Faculty of Medicine , University of Debrecen , Debrecen , Hungary.
Mária Raicsc Institute of Chemistry, University of Debrecen , Debrecen , Hungary.
Katalin E Kövérc Institute of Chemistry, University of Debrecen , Debrecen , Hungary.
Beáta Lontaya Department of Medical Chemistry, Faculty of Medicine , University of Debrecen , Debrecen , Hungary.
Ferenc Erdődia Department of Medical Chemistry, Faculty of Medicine , University of Debrecen , Debrecen , Hungary.
University of Debrecen · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several ellagitannins inhibited the activity of protein phosphatase-1 (PP1) and -2 A (PP2A) catalytic subunits (PP1c and PP2Ac) with preferential suppression of PP1c over PP2Ac. The inhibitory potency for PP1c followed the order of tellimagrandin I > mahtabin A > praecoxin B > 1.2-Di-O-galloyl-4.6-(S)-HHDP-β-D-glucopyranose > pedunculagin with IC

Indexed as

AnimalsCalorimetryCell SurvivalCerebral CortexEnzyme InhibitorsExocytosisHeLa CellsHumansHydrolyzable TanninsInhibitory Concentration 50Magnetic Resonance SpectroscopyMiceMuscle, SkeletalPhosphorylationProtein Phosphatase 1Protein Phosphatase 2Enzyme InhibitorsHydrolyzable TanninsProtein Phosphatase 1Protein Phosphatase 2SNAP25 protein, humanSynaptosomal-Associated Protein 25mahtabin Aprotein phosphatase-1protein phosphatase-2Asynaptosomal exocytosisTellimagrandin I

Identifiers

PMID30696301
PMCPMC6352937
OpenAlexW2913537803

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.